Pimozide

Tics, Delusional Parasitosis, Tourette Syndrome

Treatment

3 FDA approvals

4 Active Studies for Pimozide

What is Pimozide

Pimozide

The Generic name of this drug

Treatment Summary

Pimozide is a drug used to treat psychosis and reduce vocal and motor tics in people with Tourette Syndrome. Its exact mechanism of action is unclear, but it is believed to work by blocking dopamine receptors in the brain.

Orap

is the brand name

image of different drug pills on a surface

Pimozide Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Orap

Pimozide

1990

6

Approved as Treatment by the FDA

Pimozide, otherwise called Orap, is approved by the FDA for 3 uses including Tourette's Disorder (TD) and Tics .

Tourette's Disorder (TD)

Helps manage Tourette's Disorder (TD)

Tics

Helps manage Tics

Tourette Syndrome

Helps manage Tourette's Disorder (TD)

Effectiveness

How Pimozide Affects Patients

Pimozide is an oral medication used to treat mental illnesses. It blocks the dopamine receptors in the brain and causes changes to dopamine metabolism and function, which can provide therapeutic benefits as well as unwanted side effects. Unlike other antipsychotics, it does not cause as much sedation or low blood pressure, so it is a good alternative to haloperidol.

How Pimozide works in the body

Pimozide works to reduce tics in Tourette's Syndrome by blocking dopamine receptors in the brain.

When to interrupt dosage

The measure of Pimozide is contingent upon the perceived affliction, including Tourette's Disorder (TD), Tics and Delusional Parasitosis. The amount of dosage is contingent upon the administration method delineated in the table beneath.

Condition

Dosage

Administration

Delusional Parasitosis

1.0 mg, , 2.0 mg, 4.0 mg, 10.0 mg

, Oral, Tablet, Tablet - Oral

Tics

1.0 mg, , 2.0 mg, 4.0 mg, 10.0 mg

, Oral, Tablet, Tablet - Oral

Tourette Syndrome

1.0 mg, , 2.0 mg, 4.0 mg, 10.0 mg

, Oral, Tablet, Tablet - Oral

Warnings

Pimozide Contraindications

Condition

Risk Level

Notes

simple tics

Do Not Combine

Pulse Frequency

Do Not Combine

Cardiac Arrhythmia

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Hypomagnesemia

Do Not Combine

Pulse Frequency

Do Not Combine

Mental Depression

Do Not Combine

Pulse Frequency

Do Not Combine

Coma

Do Not Combine

Pulse Frequency

Do Not Combine

Long QT Syndrome

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Hypokalemia

Do Not Combine

Tic, Vocal

Do Not Combine

There are 20 known major drug interactions with Pimozide.

Common Pimozide Drug Interactions

Drug Name

Risk Level

Description

2,5-Dimethoxy-4-ethylamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when used in combination with Pimozide.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when used in combination with Pimozide.

4-Bromo-2,5-dimethoxyamphetamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when used in combination with Pimozide.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Pimozide.

Amisulpride

Major

Pimozide may increase the antipsychotic activities of Amisulpride.

Pimozide Toxicity & Overdose Risk

The lowest dose of the drug at which half of the test rats or mice die is 1100 mg/kg for rats and 228 mg/kg for mice.

image of a doctor in a lab doing drug, clinical research

Pimozide Novel Uses: Which Conditions Have a Clinical Trial Featuring Pimozide?

11 active studies are currently being conducted to examine the potential of Pimozide in providing relief for symptoms of Tics, Tourette's Disorder (TD) and Delusional Parasitosis.

Condition

Clinical Trials

Trial Phases

Tourette Syndrome

2 Actively Recruiting

Not Applicable

Delusional Parasitosis

0 Actively Recruiting

Tics

3 Actively Recruiting

Phase 2, Not Applicable

Pimozide Reviews: What are patients saying about Pimozide?

5

Patient Review

3/13/2010

Pimozide for Mental Disorder with Loss of Normal Personality & Reality

The generic brands for this drug aren't working, and it's Not available in India.

3.7

Patient Review

5/17/2018

Pimozide for Tourette's

This drug was effective at decreasing tics, but after having my son's hormones checked, we found that they were all messed up. I'm highly suspicious that this drug is the reason, and so we're going to try to come off of it and see if his hormones go back to normal.

3.3

Patient Review

8/18/2014

Pimozide for Tourette's

Of all the medication my grandson has taken, this one has been the most effective.

3

Patient Review

3/15/2010

Pimozide for Osteoporosis

This treatment really helped me. I'm grateful for modern medicine.

1.7

Patient Review

3/13/2018

Pimozide for Tourette's

This medication made me tired and apathetic. It would work sometimes, but I always felt worse when I was on it, so I stopped taking it. Definitely not worth it for tourettes.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about pimozide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is pimozide used for?

"Pimozide is a drug that helps to control the vocal outbursts and uncontrolled, repeated movements of the body (tics) that may interfere with the patient's normal life. It will not completely cure the tics, but will help to reduce their number and severity."

Answered by AI

Is pimozide first generation antipsychotic?

"Pimozide is a first generation antipsychotic drug which is used to treat positive symptoms including hallucinations and delusions. It is older than the second generation antipsychotic drugs."

Answered by AI

Is pimozide used for schizophrenia?

"Pimozide was formulated in the late 1960s and is still used to treat people with schizophrenia or similar mental illnesses like delusional disorder. It's usually well-tolerated, but can cause movement disorders."

Answered by AI

Clinical Trials for Pimozide

Image of Hôpital en santé mentale Rivière-des-Prairies in Montreal, Canada.

Cognitive Psychophysiological Therapy + Biofeedback for Tourette Syndrome

14 - 21
All Sexes
Montreal, Canada

The goal of this clinical trial is to compare the effectiveness of CoPs therapy with or without the therapeutic component of biofeedback in treating tics in Tourette Syndrome with emerging young adults. Hypotheses: 1. The CoPs+Biofeedback treatment will improve the severity of tics (YGTSS) and the Clinical Global Impression, surpassing the clinical significance threshold of CoPs treatment alone. 2. We expect that the identified variables (psychosocial, neurocognitive, biological) will predict the improvement of tics. Researchers will compare if the biofeedback treatment will improve the severity of tics. * In the pre-test, participants will undergo two interviews, each lasting 3 hours. These interviews will assess (through a battery of tests) the severity of tics as well as the psychosocial, biological, and neurocognitive aspects of functioning. A general assessment of intelligence and executive functions will also be conducted. * They will next attend 10 to 12 therapy sessions, with or without biofeedback. (The biofeedback component is explained in more detail in the ''Study Design'' section). * The post-test follow-ups consist of two evaluations: one 3 months after the end of the treatment and the other 6 months after. The evaluation will be done using the same battery of tests as during the pre-test interview.

Recruiting
Has No Placebo

Hôpital en santé mentale Rivière-des-Prairies (+2 Sites)

Julie Leclerc, Psychology

Image of University of Minnesota in Minneapolis, United States.

CBIT + TMS for Tics

12 - 21
All Sexes
Minneapolis, MN

Chronic tics are a disabling neuropsychiatric symptom associated with multiple child-onset mental disorders. Chronic tics affect 1-3% of youth 1 and are associated with impaired functioning, emotional and behavioral problems, physical pain, diminished quality of life, peer victimization, and a fourfold increased risk of suicide compared to the general population. Large randomized trials have demonstrated the superiority of CBIT over supportive therapy in child and adult patients. However, in these trials, only 52% of children and 38% of adults showed clinically meaningful tic improvement, meaning that 50-60% of patients do not benefit from CBIT. CBIT success relies on an ability to suppress tics that many youth lack. The central aim of CBIT is to enhance voluntary tic suppression. Better tic suppression ability drives CBIT improvement 10 and predicts lower tic burden over the course of illness. During the core CBIT procedure, competing response training, patients learn to inhibit tics by engaging in a competing motor action. However, research shows that many youth lack this fundamental tic suppression ability that CBIT aspires to enhance. This study will examine the clinical and neural effects of a treatment combining Comprehensive Behavioral Intervention for Tics (CBIT) and transcranial magnetic stimulation (TMS) to the supplementary motor area (SMA) in young people with tic disorder.

Phase 2
Recruiting

University of Minnesota

Christine Conelea